The global snake antivenom market, valued at USD 332.73 million in 2023, is expected to experience robust growth, projected to expand at a CAGR of 7.5% during the forecast period (2024–2031). Increasing snakebite cases, especially in tropical and rural regions, rising public health funding, and growing research investments in biologics and toxin-neutralizing therapies...